- $635.71m
- -$28.72m
- €155.84m
- 61
- 27
- 32
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.98 | ||
| Price to Tang. Book | 0.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.15% | ||
| Return on Equity | 3.84% | ||
| Operating Margin | -24.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 31.25 | 34.76 | 172.83 | 54 | 155.84 | 64.76 | 67.95 | 53.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 10th, 2020
- Public Since
- July 2nd, 2020
- No. of Shareholders
- 40
- No. of Employees
- 297
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 121,550,169
- Address
- Paul Ehrlich-Strasse 15, TUEBINGEN, 72076
- Web
- https://immatics.com/
- Phone
- +49 70715397700
- Contact
- Jordan Silverstein
- Auditors
- PricewaterhouseCoopers GmbH
Upcoming Events for IMTX
Q1 2025 Immatics NV Earnings Release
Immatics NV at Jefferies Global Healthcare Conference
Immatics NV Annual Shareholders Meeting
Q2 2025 Immatics NV Earnings Release
Similar to IMTX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Immatics NV share price?
As of Today at 21:16 UTC, shares in Immatics NV are trading at $5.23. This share price information is delayed by 15 minutes.
How has the Immatics NV share price performed this year?
Shares in Immatics NV last closed at $5.23 and the price had moved by -51.97% over the past 365 days. In terms of relative price strength the Immatics NV share price has underperformed the S&P500 Index by -56.69% over the past year.
What are the analyst and broker recommendations for Immatics NV?
The overall consensus recommendation for Immatics NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immatics NV dividend yield?
Immatics NV does not currently pay a dividend.
Does Immatics NV pay a dividend?
Immatics NV does not currently pay a dividend.
When does Immatics NV next pay dividends?
Immatics NV does not currently pay a dividend.
How do I buy Immatics NV shares?
To buy shares in Immatics NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immatics NV?
As of the previous close price of $5.23, shares in Immatics NV had a market capitalisation of $635.71m.
Where are Immatics NV shares listed?
Here are the trading details for Immatics NV:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMTX
What kind of share is Immatics NV?
Based on an overall assessment of its quality, value and momentum Immatics NV is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immatics NV share price forecast for 2025?
The analyst consensus target price for shares in Immatics NV is $15.25. That is 191.51% above the last closing price of $5.23.
Analysts covering Immatics NV currently have a consensus Earnings Per Share (EPS) forecast of -€1.24 for the next financial year.
Find out moreWhat is the trend in the Immatics NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immatics NV. Over the past six months, its share price has underperformed the S&P500 Index by -43.69%.
As of the last closing price of $5.23, shares in Immatics NV were trading -34.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immatics NV PE Ratio?
The Immatics NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immatics NV?
We do not have data on Immatics NV's directors